Log in to search using one of your social media accounts:

 

Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER –Medicare Cohort

We used the Surveillance, Epidemiology, and End Results (SEER) –Medicare-linked database to characterize the patterns of presentation, treatment, and survival in older diffuse large B-cell lymphoma (DLBCL) patients with concomitant autoimmune disease. DLBCL patients with autoimmune disease were more likely to be female but otherwise did not differ significant ly from other DLBCL patients in demographic data, treatment, or clinical outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Conclusion In the present retrospective claims-based cohort of older patients with DLBCL, concomitant AI disease was uncommon and was more likely to occur in female DLBCL patients, which likely reflects the greater incidence of AI disease in women. The possibility of lower LRS for SLE patients should be explored in future studies. Micro-Abstract We used the Surveillance, Epidemiology, and End Results (SEER)–Medicare-linked database to characterize the patterns of presentation, treatment, and survival in older diffuse large B-cell lymphoma (DLBCL) patients with concomitant autoimmune disease. DLBCL patients with autoi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions In this retrospective claims-based cohort of older patients with DLBCL, concomitant AI disease was uncommon and was more likely to occur in female DLBCL patients, which likely reflects the higher incidence of AI disease in women. The possibility of lower LRS for SLE patients should be explored in future studies. Teaser We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to characterize patterns of presentation, treatment, and survival in older DLBCL patients with concomitant autoimmune disease. DLBCL patients with autoimmune disease were more likely to be female, but otherwis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Splenic marginal zone lymphoma (SMZL) is an indolent B-cell lymphoma frequently associated with monoclonal gammopathy and autoimmune disorders. Therefore, whereas it is well known that the prevalence of autoimmune hemolytic anemia (AIHA) is highest in the more advanced stages of the disease and may depend on the type of treatment administered.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Zaher K. Otrock, Naval Daver, Charles S. Eby Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by excessive activation of the immune system, resulting in overproduction of inflammatory cytokines. Patients usually present with high fever, cytopenias, hyperferritinemia, and hepatosplenomegaly, and their disease process ranges from mild to fatal multiorgan failure. HLH is a heterogeneous group of disorders that can be triggered by infections, neoplasms, or autoimmune diseases. The HLH diagnosis can b...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 23 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack, Tamar Tadmor Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world, characterized by the presence of long-lived circulating leukemic cells in the peripheral blood which may infiltrate all organs, particularly those of the reticulo- endothelial system. Liver enlargement and elevation of liver enzymes related to specific involvement by the underlying disease are well-recognized features in these patients. In CLL the differential diagnosis of...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The chimeric anti-CD20 monoclonal antibody rituximab is widely used for the treatment of B-cell lymphoproliferative disorders as well as for autoimmune diseases. Rituximab induces depletion of the peripheral B cell pool, leading to hypoglobulinemia which results in decreased antibody response to infections. Enteroviral infection can cause life-threatening meningoencephalitis and other systemic chronic syndromes in immune deficient patients
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusion MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. Micro-Abstract Little is known regarding myelodysplastic syndromes (MDS) in the younger population. This retrospective review reviewed the characteristics, outcomes, and response to treatment in the adolescent and young adult (AYA) population compared to an older population. MDS was found to be rare and more aggressive in AYA. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation o...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Anait L. Melikyan, Elena K. Egorova, Hunan L. Julhakyan, Alla L. Kovrigina, Valeriy G. Savchenko Castleman disease (CD) is rare lymphoproliferative disorder with local lesionsor with multiple lessions (multicentric CD [MCD]–usually with plasma cell or mix cell morphology). Patients with human herpesvirus (HHV) type 8-positive MCD were included in a separate group owing to its extremely aggressive course and the high risk of transformation into HHV8+ plasmablastic lymphoma. At our hematologic center, from 199...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSION: MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. PMID: 27521325 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
This article will review the use of bortezomib and other proteasome inhibitors in both adult and pediatric populations, with a focus on their use in pediatrics. Expert Commentary: Bortezomib moved into the pediatric oncology arena with encouraging results in multiple early phase trials for relapsed acute lymphoblastic leukemia and acute myeloid leukemia. Bortezomib is also being studied in the treatment of non-malignant disorders, including antibody-mediated allograft rejection, graft-versus-host disease, and autoimmune cytopenias. The numerous applications of bortezomib have inspired the development of second-generation p...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
More News: Autoimmune Disease | Databases & Libraries | Epidemiology | Hematology | Leukemia | Lymphoma | Medicare | Myeloma | Study